Articles
29 May 2009
Vol. 1 No. 4: Nordic von Willebrand Workshop 2004
0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Concentrated von Willebrand factor for treating patients with von Willebrand disease

Authors

For patients with von Willebrand disease, functional levels of circulating von Willebrand factor (VWF) need to be raised to establish hemostasis or prevent excessive or delayed bleeding as immediately prior to and then after invasive procedures. For the common, mild deficiencies, an initial response to DDAVP (desmopressin) is usually sufficient for hemostasis; additional or follow-up dosing may be required, however. For those patients in whom an adequate hemostatic response cannot be achieved with DDAVP, on in whom DDAVP is contraindicated, treatment or supplementation with a plasma-derived concentrate containing VWF is necessary. The functional content of VWF in concentrates varies, however, and optimal dosing in terms of activity and frequency remain to be defined. For perspective, previous clinical usage of cryoprecipitate is compared to recent series with different concentrates. The latter include use to provide hemostasis for acute bleeding episodes or to prevent excessive bleeding from invasive procedures including surgeries.

Altmetrics

Downloads

Citations

Supporting Agencies

How to Cite



Concentrated von Willebrand factor for treating patients with von Willebrand disease. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(4). https://doi.org/10.4081/hmr.v1i4.241